170 related articles for article (PubMed ID: 35156331)
1. Application of a high-resolution in vitro human MDR1-MDCK assay and in vivo studies in preclinical species to improve prediction of CNS drug penetration.
Jiang L; Kumar S; Nuechterlein M; Reyes M; Tran D; Cabebe C; Chiang P; Reynolds J; Carrier S; Sun Y; Eddershaw P; Hay T; Chen W; Feng B
Pharmacol Res Perspect; 2022 Feb; 10(1):e00932. PubMed ID: 35156331
[TBL] [Abstract][Full Text] [Related]
2. Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier.
Colclough N; Alluri RV; Tucker JW; Gozalpour E; Li D; Du H; Li W; Harlfinger S; O'Neill DJ; Sproat GG; Chen K; Yan Y; McGinnity DF
Drug Metab Dispos; 2024 Jan; 52(2):95-105. PubMed ID: 38071533
[TBL] [Abstract][Full Text] [Related]
3. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
4. Screening novel CNS drug candidates for P-glycoprotein interactions using the cell line iP-gp: In vitro efflux ratios from iP-gp and MDCK-MDR1 monolayers compared to brain distribution data from mice.
Ozgür B; Saaby L; Janfelt C; Langthaler K; Eneberg E; Jacobsen AM; Badolo L; Montanari D; Brodin B
Eur J Pharm Biopharm; 2021 Dec; 169():211-219. PubMed ID: 34756975
[TBL] [Abstract][Full Text] [Related]
5. Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.
Patel NC; Feng B; Hou X; West MA; Trapa PE; Sciabola S; Verhoest P; Liras JL; Maurer TS; Wager TT
ACS Chem Neurosci; 2021 Mar; 12(6):1007-1017. PubMed ID: 33651587
[TBL] [Abstract][Full Text] [Related]
6. Validation of Human MDR1-MDCK and BCRP-MDCK Cell Lines to Improve the Prediction of Brain Penetration.
Feng B; West M; Patel NC; Wager T; Hou X; Johnson J; Tremaine L; Liras J
J Pharm Sci; 2019 Jul; 108(7):2476-2483. PubMed ID: 30794795
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder.
Callegari E; Malhotra B; Bungay PJ; Webster R; Fenner KS; Kempshall S; LaPerle JL; Michel MC; Kay GG
Br J Clin Pharmacol; 2011 Aug; 72(2):235-46. PubMed ID: 21392072
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
Chen EC; Broccatelli F; Plise E; Chen B; Liu L; Cheong J; Zhang S; Jorski J; Gaffney K; Umemoto KK; Salphati L
Mol Pharm; 2018 Nov; 15(11):5103-5113. PubMed ID: 30222362
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
[TBL] [Abstract][Full Text] [Related]
10. Solute Carrier Family of the Organic Anion-Transporting Polypeptides 1A2- Madin-Darby Canine Kidney II: A Promising In Vitro System to Understand the Role of Organic Anion-Transporting Polypeptide 1A2 in Blood-Brain Barrier Drug Penetration.
Liu H; Yu N; Lu S; Ito S; Zhang X; Prasad B; He E; Lu X; Li Y; Wang F; Xu H; An G; Unadkat JD; Kusuhara H; Sugiyama Y; Sahi J
Drug Metab Dispos; 2015 Jul; 43(7):1008-18. PubMed ID: 25908246
[TBL] [Abstract][Full Text] [Related]
11. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system pharmacokinetics of the Mdr1 P-glycoprotein substrate CP-615,003: intersite differences and implications for human receptor occupancy projections from cerebrospinal fluid exposures.
Venkatakrishnan K; Tseng E; Nelson FR; Rollema H; French JL; Kaplan IV; Horner WE; Gibbs MA
Drug Metab Dispos; 2007 Aug; 35(8):1341-9. PubMed ID: 17470526
[TBL] [Abstract][Full Text] [Related]
13. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models.
Hellinger E; Veszelka S; Tóth AE; Walter F; Kittel A; Bakk ML; Tihanyi K; Háda V; Nakagawa S; Duy TD; Niwa M; Deli MA; Vastag M
Eur J Pharm Biopharm; 2012 Oct; 82(2):340-51. PubMed ID: 22906709
[TBL] [Abstract][Full Text] [Related]
14. Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules.
Gupta M; Feng J; Bhisetti G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542901
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
16. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
[TBL] [Abstract][Full Text] [Related]
17. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.
Kikuchi R; de Morais SM; Kalvass JC
Drug Metab Dispos; 2013 Dec; 41(12):2012-7. PubMed ID: 24009309
[TBL] [Abstract][Full Text] [Related]
18. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
19. Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
Sane R; Agarwal S; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Apr; 345(1):111-24. PubMed ID: 23397054
[TBL] [Abstract][Full Text] [Related]
20. Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model.
Kosugi Y; Mizuno K; Santos C; Sato S; Hosea N; Zientek M
AAPS J; 2021 May; 23(4):72. PubMed ID: 34008121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
